We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
21 Jun 2021 - 24 Jun 2021

Serum Catestatin Level Is Increased in Women with Preeclampsia

By LabMedica International staff writers
Posted on 24 May 2021
Print article
Image: An enzyme immunoassay for human serum catestatin (Photo courtesy of RayBiotech)
Image: An enzyme immunoassay for human serum catestatin (Photo courtesy of RayBiotech)
Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. Preeclampsia usually begins after 20 weeks of pregnancy in women whose blood pressure had been normal.

Catestatin is a cationic and hydrophobic peptide that can stimulate histamine release from mast cells and exhibits potent catecholamine release-inhibitory activity. Catestatin can inhibit catecholamine release from chromaffin cells and adrenergic neurons. Catestatin can also have a strong vasodilator effect. This may be useful in understanding the pathophysiology of preeclampsia and its treatment.

Medical Scientists at the Istanbul University-Cerrahpas (Istanbul, Turkey) and their international colleagues investigated the serum catestatin levels in pregnant women with and without preeclampsia. They evaluated 50 consecutive women with mild preeclampsia, 50 consecutive women with severe preeclampsia, and 100 consecutive pregnant women with a gestational age-matched (±1 week) uncomplicated pregnancy in a cross-sectional study.

The team reported that the mean serum catestatin was significantly increased in the preeclampsia group compared to the control group (290.7 ± 95.5 pg/mL versus 182.8 ± 72.0 pg/mL). Mean serum catestatin was comparable in mild and severe preeclampsia groups (282.7 ± 97.9 pg/mL versus 298.7 ± 93.4 pg/mL). Serum catestatin levels had positive correlations with systolic and diastolic blood pressure, urea, uric acid, and creatinine. In conclusion, serum catestatin levels are increased in preeclamptic pregnancies compared to gestational age-matched controls.

The authors concluded that serum catestatin levels were found to be correlated with clinical and laboratory data of preeclampsia. This highlights the importance of chromaffin cell secretions in the adrenal medulla in preeclampsia. This study will help understand the role of the adrenal medulla in the autonomic nervous system dysregulation in preeclampsia. Also, control of serum catestatin levels may support the treatment of hypertension in preeclampsia. The study was published in the May, 2021 issue of the Journal of Obstetrics and Gynaecology.

Related Links:
Istanbul University-Cerrahpas

Gold Supplier
Thrombin Generation System
ST Genesia
New
COVID-19 Test
CLART COVID-19
New
Refrigerated Centrifuge
Centrisart G-26C
New
COVID-19 Sampling and Viral RNA Extraction Kit
Bosphore COVID-19 Sampling and Viral RNA Extraction Kit

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Illustration

Global Clinical Chemistry Analyzers Market to Reach USD 15.97 Billion by 2028

The global clinical chemistry analyzers market is projected to grow at a CAGR of 4.25% from USD 11.45 billion in 2020 to USD 15.97 billion by 2028, driven by growth in technology, rising global population,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.